These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8603812)

  • 1. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions.
    Puisieux I; Bain C; Merrouche Y; Malacher P; Kourilsky P; Even J; Favrot M
    Int J Cancer; 1996 Apr; 66(2):201-8. PubMed ID: 8603812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
    Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.
    Gaudin C; Dietrich PY; Robache S; Guillard M; Escudier B; Lacombe MJ; Kumar A; Triebel F; Caignard A
    Cancer Res; 1995 Feb; 55(3):685-90. PubMed ID: 7834641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
    Wang QJ; Hanada K; Robbins PF; Li YF; Yang JC
    Cancer Res; 2012 Dec; 72(23):6119-29. PubMed ID: 23071066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.
    Mitropoulos D; Kooi S; Rodriguez-Villanueva J; Platsoucas CD
    Clin Exp Immunol; 1994 Aug; 97(2):321-7. PubMed ID: 8050183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
    Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
    Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.
    Weidmann E; Whiteside TL; Giorda R; Herberman RB; Trucco M
    Cancer Res; 1992 Nov; 52(21):5913-20. PubMed ID: 1382847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
    Kurokawa T; Oelke M; Mackensen A
    Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
    Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas.
    Zhang Q; Jia Q; Deng T; Song B; Li L
    Biochem Biophys Res Commun; 2015 Feb; 458(1):70-6. PubMed ID: 25637538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ demonstration of renal-cell-carcinoma-specific T-cell clones.
    Caignard A; Guillard M; Gaudin C; Escudier B; Triebel F; Dietrich PY
    Int J Cancer; 1996 May; 66(4):564-70. PubMed ID: 8635875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
    Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
    J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A; Muul LM; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
    Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
    Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
    Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
    Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.